Biogen and Eisai, Co., Ltd. are discontinuing global Phase III trials, ENGAGE and EMERGE, evaluating the efficacy and safety of aducanumab in mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease dementia. The decision is based on results of a futility analysis conducted by an independent data monitoring committee, which indicated the trials were unlikely to meet their primary endpoint upon completion. The recommendation to stop the studies was not based on safety con...